Jining's pharmaceutical core industry chain integration and solid chain action raw material drug (sodium hyaluronate) special event enters the focus, Furuida

recently, the Jining Pharmaceutical Core Industry Chain Integration and Consolidation Action - Raw Material Drug (Sodium Hyaluronate) Special Event was successfully held at Focusfreda. The event was led by the Jining Pharmaceutical Industry Special Team and invited multiple enterprises in the Jining Pharmaceutical Core Industry Chain and Supply Chain to participate. The aim is to strengthen communication and cooperation between upstream and downstream enterprises in the pharmaceutical grade sodium hyaluronate industry chain, continuously enhance the resilience and competitiveness of the industry chain and supply chain, and improve the modernization level of the pharmaceutical core industry chain.

The attending representatives first visited the Focusfreda Sodium Hyaluronate Production Base, went into the production workshop to gain a deeper understanding of the fermentation, purification, and refining processes of pharmaceutical grade sodium hyaluronate, went into the warehouse to experience the storage environment of different products such as raw materials and finished products, and went into the R&D laboratory to feel the company's strict control and pursuit of excellence in product quality, demonstrating the vigorous vitality of Focusfreda's production and operation, and receiving high recognition and affirmation from on-site visitors.

Subsequently, the Jining Pharmaceutical Core Industry Chain Integration and Consolidation Action - Raw Material Drug (Sodium Hyaluronate) Matchmaking Meeting was officially held. Li Dapeng, Director of the Pharmaceutical Industry Special Team of the Manufacturing Strong City (New Industrialization) Construction Command, presided over the meeting and delivered a speech.

He stated that the convening of this event is in line with the decision-making and deployment requirements of the Provincial Party Committee and Provincial Government to promote industrial chain cooperation, facilitate the integration and innovation of large, medium, and small enterprises. The purpose is to strengthen the product chain cooperation between upstream and downstream enterprises in the city, promote the growth of the industrial chain, and create industrial clusters. As the main enterprise of the biopharmaceutical core industry chain in Jining City, Focusfreda's main product, sodium hyaluronate, has a wide range of applications and has a broad impact on downstream industries. The purpose of holding a special docking meeting for raw material sodium hyaluronate at Focusfreda is to promote this category throughout the city, deepen cooperation between upstream and downstream enterprises, and also hope that Focusfreda can leverage its own advantages to play a more driving role in the industry of sodium hyaluronate chain in Jining City.

Liu Lei, General Manager of Focusfreda, warmly welcomed the visit of the pharmaceutical industry special team and industry chain enterprises. He expressed gratitude to the leaders of the special team and industry colleagues for their guidance and support to Focusfreda, and provided a detailed introduction on the company culture, development history, industry status, research and development advantages, honors and qualifications, export scale, and other related information. Liu Lei stated that in recent years, with the accelerated empowerment of Furuida's technology, talent, channels, and resources, and the collaborative efforts of its subordinate modules, Focusfreda has taken firm and orderly steps towards the strategic transformation and upgrading of the high-end pharmaceutical industry. Raw material registration projects in multiple countries and regions such as China, the European Union, the United States, South Korea, and India are being promoted in an orderly manner, achieving a series of breakthrough results.

Cao Yu, the head of Focusfreda's API Business Unit, highlighted the industry segmentation of pharmaceutical grade sodium hyaluronate applications, as well as the company's technological advantages, process advantages, quality advantages, and production capacity guarantees in the supply of pharmaceutical grade sodium hyaluronate raw materials. At present, the company has an independent high-level clean workshop that complies with GMP standards, a complete quality system, and full lifecycle supervision of products from raw material procurement to product release. The product quality meets the requirements of pharmacopoeias such as EP, JP, BP, and impurities such as proteins, nucleic acids, and endotoxins are much lower than EP requirements.

At the conference, representatives from Chenxin Fodu Pharmaceutical, Guangming Pharmaceutical, Jiu'er Industrial Group, Nuomingkang Pharmaceutical Research Institute, Yizhengda Pharmaceutical Technology and other enterprises spoke one after another, sharing their current application of active pharmaceutical ingredients (sodium hyaluronate) and conducting on-site exchanges on the next steps of cooperation.

More than 20 people participated in the event, including the person in charge of the municipal pharmaceutical industry special team, the director of the relevant (county, district) pharmaceutical industry special team, the person in charge of the city's pharmaceutical core industry chain and supply chain related enterprises, enterprise support cadres, and the person in charge of relevant departments of Focusfreda.